Norgine Bolsters Rare Disease Portfolio with Theravia Acquisition

Deal News | Apr 15, 2025 | PR Newswire Cision Norgine

Norgine, a specialty pharmaceutical and consumer healthcare company, has entered into a definitive agreement to acquire Theravia, an international pharmaceutical company focusing on treatments for rare diseases. The acquisition is part of Norgine's strategy to enhance its portfolio in the rare disease segment, following recent deals with Fennec Pharma and X4 Pharma. Theravia's product offerings include SIKLOS® and ORPHACOL®, medicines for sickle cell disease and a genetic disorder affecting bile production, respectively. This acquisition is expected to strengthen Norgine's position in Europe and expand its rare disease portfolio to six core products. The deal is significant for Norgine as it seeks to grow through acquisitions and in-licensing opportunities. The transaction is subject to regulatory approvals and reflects Norgine's ongoing commitment to delivering innovative treatments to patients globally.

Sectors

  • Pharmaceuticals
  • Healthcare

Geography

  • Europe – Both Norgine and Theravia are based in Europe, and the acquisition will strengthen Norgine's market position within this region.
  • France – Theravia's majority shareholder, Mérieux Equity Partners, is based in France, which is a key location mentioned in the context of the transaction.

Industry

  • Pharmaceuticals – The primary focus of the article is the acquisition of Theravia, a pharmaceutical company specializing in rare diseases, by Norgine, which itself is involved in the pharmaceutical industry.
  • Healthcare – The article discusses the acquisition in the context of adding products to Norgine's existing healthcare offerings that target rare diseases, highlighting the healthcare relevance of the transaction.

Financials

    Participants

    NameRoleTypeDescription
    NorgineAcquirerCompaniesNorgine is a specialty pharmaceutical and consumer healthcare company focused on delivering innovative treatments for rare and specialty diseases.
    TheraviaTargetCompaniesTheravia is an international pharmaceutical laboratory specializing in rare or neglected diseases, now acquired by Norgine.
    Mérieux Equity PartnersSelling CompanyCompaniesMérieux Equity Partners is a healthcare-specialized investment firm, the majority shareholder of Theravia prior to Norgine's acquisition.
    Fennec PharmaOther CompaniesCompaniesA company recently partnered with Norgine for the rare disease medicine PEDMARQSI®.
    X4 PharmaceuticalsOther CompaniesCompaniesA company involved with Norgine in the marketing and distribution of mavorixafor for the treatment of WHIM syndrome.